Genentech, Inc. (“Genentech”) (NYSE: DNA) has been sued by its shareholders in connection with Genentech’s proposed $43.7 billion buyout by majority shareholder Roche Holding AG (“Roche”). Finkelstein Thompson is investigating these claims, and welcomes inquiries by Genentech shareholders concerning their rights and interests in connection with this matter. Roche’s offer is to buy all outstanding shares of Genentech for $89 a share. Currently, shares of Genentech are trading above that price. According to the lawsuit, Genentech’s directors were and are unable to negotiate a fair price because Roche already owns 55.9 percent of Genentech. Interested Genentech shareholders can reach Finkelstein Thompson’s Washington, D.C. office at (877) 337-1050 or by email.